We are live on ! Find out more
WVE icon

Wave Life Sciences

162 hedge funds and large institutions have $986M invested in Wave Life Sciences in 2024 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 61 increasing their positions, 38 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 17

108% more capital invested

Capital invested by funds: $474M → $986M (+$512M)

61% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 38

32% more call options, than puts

Call options by funds: $1.49M | Put options by funds: $1.13M

16.28% more ownership

Funds ownership: 77.62%93.91% (+16%)

13% more funds holding

Funds holding: 144162 (+18)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
162
Holders Change
+18
Holders Change %
+12.5%
% of All Funds
2.33%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
36
Increased
61
Reduced
38
Closed
17
Calls
$1.49M
Puts
$1.13M
Net Calls
+$360K
Net Calls Change
+$520K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$149M
MC
2
Maverick Capital
Texas
$82.4M +$14.2M +2,378,159 +31%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$79.6M +$26M +4,345,632 +81%
BlackRock
4
BlackRock
New York
$59.8M +$3.35M +559,688 +8%
MCM
5
M28 Capital Management
Connecticut
$50.5M
DCM
6
Driehaus Capital Management
Illinois
$48M +$29.6M +4,950,764 +545%
SL
7
Siren LLC
Connecticut
$46.9M +$34.2M +5,721,172 New
KCM
8
Kynam Capital Management
New Jersey
$40.2M +$5.52M +923,976 +23%
6CM
9
683 Capital Management
New York
$34.4M -$6.72M -1,125,000 -21%
BG
10
Bellevue Group
Switzerland
$33.6M
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$25.6M +$10.1M +1,687,333 +117%
Vanguard Group
12
Vanguard Group
Pennsylvania
$23.7M +$2.81M +469,866 +19%
EA
13
Emerald Advisers
Pennsylvania
$23.6M +$2.32M +388,280 +16%
Primecap Management
14
Primecap Management
California
$21.2M -$499K -83,516 -3%
State Street
15
State Street
Massachusetts
$19M +$346K +57,822 +3%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$18.6M +$1.69M +283,419 +14%
EMFAT
17
Emerald Mutual Fund Advisers Trust
Pennsylvania
$17.4M +$1.81M +302,528 +17%
Artisan Partners
18
Artisan Partners
Wisconsin
$16.1M +$11.7M +1,960,470 New
Fidelity Investments
19
Fidelity Investments
Massachusetts
$12.6M +$5.85M +979,110 +175%
AAA
20
Affinity Asset Advisors
New York
$11.5M +$6.13M +1,025,000 +273%
TPC
21
Takeda Pharmaceutical Company
Japan
$11M
Citadel Advisors
22
Citadel Advisors
Florida
$7.69M +$5.46M +912,870 +3,693%
RI
23
RTW Investments
New York
$7.38M +$5.38M +900,000 New
Millennium Management
24
Millennium Management
New York
$6.98M -$4.86M -812,635 -49%
MS
25
Maven Securities
Jersey
$6.97M +$5.08M +850,000 New

WVE Hedge Fund Activity: Q3 2024 in Review

162 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Wave Life Sciences (WVE) for Q3 2024, worth a combined $986M — up 108% from $474M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new WVE positions and 17 closed out — a net gain of 19 holders — while 61 added to existing stakes and 38 trimmed.

The largest buyer was Driehaus Capital Management, adding an estimated $29.6M. The largest seller was Artal Group, exiting entirely with an estimated $22.8M sold.

  • 162 institutional investors held Wave Life Sciences (WVE) as of Q3 2024, up from 144 in Q2 2024.
  • Funds reported $986M of Wave Life Sciences stock for Q3 2024, up 108% quarter-over-quarter.
  • 36 funds opened new Wave Life Sciences positions in Q3 2024 and 17 closed out, a net change of +19 holders.
  • The largest Wave Life Sciences buyer in Q3 2024 was Driehaus Capital Management, an estimated $29.6M added.
  • The largest Wave Life Sciences seller in Q3 2024 was Artal Group, an estimated $22.8M sold.

Based on aggregated 13F filings for Q3 2024.